Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate

Oncogene volume 37, pages 5175–5190 (2018)Cite this article

Subjects

Abstract

Monoamine oxidase A (MAOA) is a mitochondrial enzyme, which degrades monoamine neurotransmitters and dietary amines and produces H2O2. Recent studies have shown increased MAOA expression in prostate cancer (PCa), glioma, and classical Hodgkin lymphoma. However, the biological function of MAOA in cancer development remains unknown. In this study, we investigated the role of MAOA in the development of prostate adenocarcinoma by creating a prostate-specific Pten/MAOA knockout (KO) mouse model, in which MAOA-floxP mouse was crossed with the conditional Pten KO PCa mouse that develops invasive PCa. In contrast to Pten KO mice, age-matched Pten/MAOA KO mice exhibited a significant decrease in both prostate size and the incidence of invasive cancer. We observed a significant decline in AKT phosphorylation and Ki67 expression in Pten/MAOA KO mice, which reduced epithelial cell growth and proliferation. As cancer stem cells (CSCs) are required for tumor initiation and growth, we investigated expression of OCT4 and NANOG in the setting of decreased MAOA expression. We found that both OCT4 and NANOG were significantly attenuated in the prostate epithelia of Pten/MAOA KO mice compared to Pten KO mice, which was confirmed with targeted knockdown of MAOA with a short-hairpin(sh) vector targeting MAOA compared to cells transfected with a control vector. Expression of other markers associated with the a stem cell phenotype, including CD44, α2β1, and CD133 as well as HIF-1α+CD44+ stem cells were all decreased in shMAOA PCa cells compared with empty vector-transfected control cells. We also found spheroid formation ability in PCa cells was decreased when endogenous MAOA was suppressed by siRNA or MAOA inhibitor clorgyline in a colony formation assay. Using the TCGA database, elevated MAOA expression was associated with reduced Pten levels in high Gleason grade in patient samples. Further, we found that Pten-positive PCa cells were more resistant to clorgyline treatments than Pten-null cells in tumorigenicity and stemness. Taken together, these studies suggest that MAOA expression promotes PCa development by increasing cell proliferation and CSCs and highlights the potential use of MAOA inhibitors for the treatment of PCa.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10

References

  1. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Annu Rev Neurosci. 1999;22:197–217.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Singh C, Bortolato M, Bali N, Godar SC, Scott AL, Chen K, et al. Cognitive abnormalities and hippocampal alterations in monoamine oxidase A and B knockout mice. Proc Natl Acad Sci USA. 2013;110:12816–21.

    Article  CAS  PubMed  Google Scholar 

  3. Bach AW, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, et al. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci USA. 1988;85:4934–8.

    Article  CAS  PubMed  Google Scholar 

  4. True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA. 2006;103:10991–6.

    Article  CAS  PubMed  Google Scholar 

  5. Peehl DM, Coram M, Khine H, Reese S, Nolley R, Zhao H. The significance of monoamine oxidase-A expression in high grade prostate cancer. J Urol. 2008;180:2206–11.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Wu JB, Shao C, Li X, Li Q, Hu P, Shi C, et al. Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis. J Clin Investig. 2014;124:2891–908.

    Article  CAS  PubMed  Google Scholar 

  7. Wu JB, Lin TP, Gallagher JD, Kushal S, Chung LW, Zhau HE, et al. Monoamine oxidase A inhibitor-near-infrared dye conjugate reduces prostate tumor growth. J Am Chem Soc. 2015;137:2366–74.

    Article  CAS  PubMed  Google Scholar 

  8. Kushal S, Wang W, Vaikari VP, Kota R, Chen K, Yeh TS, et al. Monoamine oxidase A (MAO A) inhibitors decrease glioma progression. Oncotarget. 2016;7:13842–53.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Li PC, Siddiqi IN, Mottok A, Loo EY, Wu CH, Cozen W, et al. Monoamine oxidase A is highly expressed in classical Hodgkin lymphoma. J Pathol. 2017;243:220–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA: A Cancer J Clin. 2017;67:7–30.

    Google Scholar 

  11. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–7.

    Article  CAS  PubMed  Google Scholar 

  12. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009;4:127–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ, et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev. 2001;101:61–9.

    Article  CAS  PubMed  Google Scholar 

  14. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 2003;4:209–21.

    Article  CAS  PubMed  Google Scholar 

  15. Fu Y, Wey S, Wang M, Ye R, Liao CP, Roy-Burman P, et al. Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium. Proc Natl Acad Sci USA. 2008;105:19444–9.

    Article  CAS  PubMed  Google Scholar 

  16. Adisetiyo H, Liang M, Liao CP, Aycock-Williams A, Cohen MB, Xu S, et al. Loss of survivin in the prostate epithelium impedes carcinogenesis in a mouse model of prostate adenocarcinoma. PLoS ONE. 2013;8:e69484.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Gottowik J, Cesura AM, Malherbe P, Lang G, Da Prada M. Characterisation of wild-type and mutant forms of human monoamine oxidase A and B expressed in a mammalian cell line. FEBS Lett. 1993;317:152–6.

    Article  CAS  PubMed  Google Scholar 

  18. Ma J, Ito A. Tyrosine residues near the FAD binding site are critical for FAD binding and for the maintenance of the stable and active conformation of rat monoamine oxidase A. J Biochem. 2002;131:107–11.

    Article  CAS  PubMed  Google Scholar 

  19. Bortolato M, Chen K, Godar SC, Chen G, Wu W, Rebrin I, et al. Social deficits and perseverative behaviors, but not overt aggression, in MAO-A hypomorphic mice. Neuropsychopharmacology. 2011;36:2674–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Dillon LM, Miller TW. Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets. 2014;15:65–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Tuominen VJ, Ruotoistenmaki S, Viitanen A, Jumppanen M, Isola J. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res. 2010;12:R56.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA. 2009;106:268–73.

    Article  CAS  PubMed  Google Scholar 

  23. Sahlberg SH, Spiegelberg D, Glimelius B, Stenerlow B, Nestor M. Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells. PLoS ONE. 2014;9:e94621.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Dawood S, Austin L, Cristofanilli M. Cancer stem cells: implications for cancer therapy. Oncology (Williston Park). 2014;28:1101–7.

    Google Scholar 

  25. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946–51.

    Article  CAS  Google Scholar 

  26. Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev. 2004;14:43–7.

    Article  CAS  PubMed  Google Scholar 

  27. Tan BT, Park CY, Ailles LE, Weissman IL. The cancer stem cell hypothesis: a work in progress. Lab Investig. 2006;86:1203–7.

    Article  CAS  PubMed  Google Scholar 

  28. van den Berg DL, Snoek T, Mullin NP, Yates A, Bezstarosti K, Demmers J, et al. An Oct4-centered protein interaction network in embryonic stem cells. Cell Stem Cell. 2010;6:369–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 1998;58:2720–3.

    CAS  PubMed  Google Scholar 

  30. Takubo K, Goda N, Yamada W, Iriuchishima H, Ikeda E, Kubota Y, et al. Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell. 2010;7:391–402.

    Article  CAS  Google Scholar 

  31. Forristal CE, Nowlan B, Jacobsen RN, Barbier V, Walkinshaw G, Walkley CR, et al. HIF-1alpha is required for hematopoietic stem cell mobilization and 4-prolyl hydroxylase inhibitors enhance mobilization by stabilizing HIF-1alpha. Leukemia. 2015;29:1366–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.

    Article  PubMed  Google Scholar 

  33. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2016;69:428–35.

    Article  PubMed  Google Scholar 

  35. Oliveira DS, Dzinic S, Bonfil AI, Saliganan AD, Sheng S, Bonfil RD. The mouse prostate: a basic anatomical and histological guideline. Bosn J Basic Med Sci. 2016;16:8–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Liao CP, Zhong C, Saribekyan G, Bading J, Park R, Conti PS, et al. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res. 2007;67:7525–33.

    Article  CAS  PubMed  Google Scholar 

  37. Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J, et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA. 1999;96:6199–204.

    Article  CAS  PubMed  Google Scholar 

  38. Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, et al. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet. 2010;42:454–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Gu G, Yuan J, Wills M, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res. 2007;67:4807–15.

    Article  CAS  PubMed  Google Scholar 

  40. Lawson DA, Xin L, Lukacs R, Xu Q, Cheng D, Witte ON. Prostate stem cells and prostate cancer. Cold Spring Harb Symp Quant Biol. 2005;70:187–96.

    Article  CAS  PubMed  Google Scholar 

  41. Nikitin AY, Matoso A, Roy-Burman P. Prostate stem cells and cancer. Histol Histopathol. 2007;22:1043–9.

    CAS  PubMed  Google Scholar 

  42. Pfeiffer MJ, Schalken JA. Stem cell characteristics in prostate cancer cell lines. Eur Urol. 2010;57:246–54.

    Article  CAS  PubMed  Google Scholar 

  43. Liao CP, Adisetiyo H, Liang M, Roy-Burman P. Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells. Cancer Res. 2010;70:7294–303.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Liao CP, Adisetiyo H, Liang M, Roy-Burman P. Cancer stem cells and microenvironment in prostate cancer progression. Horm Cancer. 2010;1:297–305.

    Article  CAS  PubMed  Google Scholar 

  45. Adisetiyo H, Liang M, Liao CP, Jeong JH, Cohen MB, Roy-Burman P, et al. Dependence of castration-resistant prostate cancer (CRPC) stem cells on CRPC-associated fibroblasts. J Cell Physiol. 2014;229:1170–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Ting MC, Liao CP, Yan C, Jia L, Groshen S, Frenkel B, et al. An enhancer from the 8q24 prostate cancer risk region is sufficient to direct reporter gene expression to a subset of prostate stem-like epithelial cells in transgenic mice. Dis Models Mech. 2012;5:366–74.

    Article  CAS  Google Scholar 

  47. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell of origin for human prostate cancer. Science. 2010;329:568–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Leong KG, Wang BE, Johnson L, Gao WQ. Generation of a prostate from a single adult stem cell. Nature. 2008;456:804–8.

    Article  CAS  PubMed  Google Scholar 

  49. Xu S, Adisetiyo H, Tamura S, Grande F, Garofalo A, Roy-Burman P, et al. Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer. British Journal of Cancer. 2015;113:242–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. The Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell. 2015;163:1011–25..

Download references

Acknowledgements

We would like to thank Dr. Pradip Roy-Burman for providing the conditional Pten deletion mouse model and for helpful technical discussions, Bin Qian (Department of Pharmacology and Pharmaceutical Sciences, University of Southern California) for technical assistance, F. Hong for critically reading the manuscript, and all members of the Jean C. Shih Laboratory and the Center for Apply Molecular Medicine at USC for assistance in various aspects of this work.

Funding

This work was supported by the Department of Defense Prostate Cancer Research Program grant W81XWH-12-1-0282, the Daniel Tsai Family Fund, and the Boyd and Elsie Welin Professorship (to JCS). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Department of Defense or other funding agency.

Author information

Author notes

  1. These authors contributed equally: Chun-Peng Liao, Tzu-Ping Lin, Pei-Chuan Li.

Authors and Affiliations

  1. Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, 90089-9121, USA

    Chun-Peng Liao, Tzu-Ping Lin, Pei-Chuan Li, Lauren A. Geary, Kevin Chen, Vijaya Pooja Vaikari & Jean C. Shih

  2. USC-Taiwan Center for Translation Research, University of Southern California, Los Angeles, CA, 90089-9121, USA

    Chun-Peng Liao, Tzu-Ping Lin, Pei-Chuan Li, Lauren A. Geary, Kevin Chen, Vijaya Pooja Vaikari & Jean C. Shih

  3. Lawrence J. Ellison Institute for Transformative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033-9075, USA

    Chun-Peng Liao & Mitchell E. Gross

  4. Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, WA, 11221, Taiwan

    Tzu-Ping Lin & Chi-Hung Lin

  5. Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Spokane, 99210-1495, USA

    Jason Boyang Wu

  6. Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, 90089-9176, CA, USA

    Mitchell E. Gross & Jean C. Shih

  7. Department of Cell and Neurobiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90089-9037, USA

    Jean C. Shih

  8. College of Pharmacy, Taipei Medical University, Taipei, 11031, Taiwan

    Jean C. Shih

Authors
  1. Chun-Peng Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tzu-Ping Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pei-Chuan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lauren A. Geary
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kevin Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vijaya Pooja Vaikari
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jason Boyang Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chi-Hung Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mitchell E. Gross
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jean C. Shih
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean C. Shih.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liao, CP., Lin, TP., Li, PC. et al. Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate. Oncogene 37, 5175–5190 (2018). https://doi.org/10.1038/s41388-018-0325-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41388-018-0325-x

This article is cited by

Search

Advanced search

Quick links